10.21.14
SRI Biosciences has completed construction of an early-phase clinical trial facility in Plymouth, MI. The 9,400-square foot unit, located in the Michigan Life Science Innovation Center, is now open and equipped for early-stage human research studies.
The new facility includes 13 beds and 3 infusion chairs, an investigational pharmacy with the capacity to prepare sterile infusions, a lab for sample processing, accommodations for overnight stays for research participants, and equipment to monitor safety.
"Our core focus will be translational medicine research — that important stage when scientific breakthroughs move from the lab to the clinic and where their potential to improve human health can be initially evaluated," said David Sahner, M.D., senior director of clinical translation, SRI Biosciences. "When done well, early-phase clinical trials can provide critical insights — into safety, tolerability, absorption, distribution, and elimination of drugs and biologics, as well as early assessment of mechanistic and therapeutic effects — that help reduce drug development risk, pave the way for future regulatory and commercial success, and get new medicines to patients who need them more quickly."
The new facility includes 13 beds and 3 infusion chairs, an investigational pharmacy with the capacity to prepare sterile infusions, a lab for sample processing, accommodations for overnight stays for research participants, and equipment to monitor safety.
"Our core focus will be translational medicine research — that important stage when scientific breakthroughs move from the lab to the clinic and where their potential to improve human health can be initially evaluated," said David Sahner, M.D., senior director of clinical translation, SRI Biosciences. "When done well, early-phase clinical trials can provide critical insights — into safety, tolerability, absorption, distribution, and elimination of drugs and biologics, as well as early assessment of mechanistic and therapeutic effects — that help reduce drug development risk, pave the way for future regulatory and commercial success, and get new medicines to patients who need them more quickly."